Showing results (121-130 of 151) with videos related to
Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumorsFlorentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.Frontiers in Oncology|April 4, 2022
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial TumorsDavid S Hong, Marcus O Butler, Russell K Pachynski, et al.Developmental Cell|May 17, 2025
Neurodevelopmental hijacking of oligodendrocyte lineage programs drives glioblastoma infiltrationYiyan Wu, Benson Z Wu, Yosef Ellenbogen, et al.JAMA Oncology|November 18, 2017
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical CarcinomaStephanie Lheureux, Marcus O Butler, Blaise Clarke, et al.Journal for Immunotherapy of Cancer|August 6, 2020
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumorsKirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Adi Diab, Paolo A Ascierto, Michele Maio, et al.Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.Science Immunology|June 2, 2017
Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic SyndromeMagar Ghazarian, Xavier S Revelo, Mark K Nøhr, et al.Cancer Research|November 11, 2025
Response to Immune Checkpoint Blockade is Enhanced in the Presence of Hematopoietic TET2 InactivationVincent Rondeau, Suraj Bansal, Marco M Buttigieg, et al.The New England Journal of Medicine|September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.Pageof 16